Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | Director · Executive Chair | July 17, 2026 | August 11, 2026 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | April 30, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date July 17, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,261 |
Ending reported balance
After 2026-08-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-07-17 · Exercise / conversion · Acquired 1 · Balance 1 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Row 2 · 2026-08-06 · Exercise / conversion · Acquired 1,666 · Balance 1,667 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Row 3 · 2026-08-06 · Tax withholding · Disposed 406 · Balance 1,261 F2: Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-17 · Exercise / conversion · Disposed 1 · Balance 0 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3: On July 17, 2024, the reporting person was granted 22,325 (1 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-06 · Exercise / conversion · Disposed 1,666 · Balance 0 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F4: On August 6, 2025, the reporting person was granted 30,000 (1,666 post-split) RSUs, vesting on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2: Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs.
F3: On July 17, 2024, the reporting person was granted 22,325 (1 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025.
F4: On August 6, 2025, the reporting person was granted 30,000 (1,666 post-split) RSUs, vesting on the first anniversary of the date of grant.
Emergent BioSolutions Inc.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 113,839 |
Reported balance
After 2026-04-30 transaction · row 1
1 source rowRow 1 · 2026-04-30 · Grant · Acquired 25,344 · Balance 113,839 F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2033-04-30 | Direct | 11,296 |
Reported balance
After 2026-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-30 · Grant · Acquired 11,296 · Balance 11,296 F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CoLucid Pharmaceuticals, Inc.
Report date March 01, 2017 · Filed March 01, 2017
Section 16 reporting ended · disclosed 2017-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2025-07-09 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-01 · Disposition to issuer · Disposed 6,577 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.50 · Expires 2026-01-04 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-01 · Disposition to issuer · Disposed 997 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.24 · Expires 2026-05-10 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-01 · Disposition to issuer · Disposed 8,897 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.62 · Expires 2026-07-01 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-03-01 · Disposition to issuer · Disposed 1,630 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.20 · Expires 2027-01-03 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-03-01 · Disposition to issuer · Disposed 453 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
F2: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2020 Filed Mar 19, 2020 22:35 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 303,200 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001019056-20-000244 · white.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,200 Underlying: Common Stock · 303,200 shares Expires 2030-02-17 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on February 17, 2021. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:56 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 189,894 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001019056-19-000620 · white.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,894 Underlying: Common Stock · 189,894 shares Expires 2029-10-31 F1 · derivative.exercise_date: The options vest on November 1, 2020, the one-year anniversary of the grant date. Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 17:58 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 50,000 | $0.88 | $44,000.00 |
DisclosureSEC source: 0001593968-19-001428 · primary_01.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,603 F1 · price: The purchase price of $0.88 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.85 to $0.88. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 20, 2019 Filed May 20, 2019 23:22 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 30,000 | $0.81 | $24,300.00 |
DisclosureSEC source: 0001593968-19-001149 · primary_01.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,603 Read SEC document |
| May 14, 2019 Filed May 15, 2019 01:27 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 10,000 | $0.78 | $7,800.00 |
DisclosureSEC source: 0001019056-19-000291 · white.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,603 Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 02:10 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 151,600 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001019056-19-000186 · white.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,600 Underlying: Common Stock · 151,600 shares Expires 2029-02-28 F1 · derivative.exercise_date: The options vest in three approximately equal annual installments beginning on February 28, 2020. Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 15:23 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 10,000 | $2.38 | $23,800.00 |
DisclosureSEC source: 0001019056-18-001110 · white_4.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,603 F1 · price: The purchase price of $2.38 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $2.38 to $2.39. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 21, 2018 Filed May 23, 2018 20:08 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Unit Stock · Derivative | 35,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-18-000739 · white_4.xml · derivative · entry 3 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,644 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on May 21, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs fully vested on May 21, 2018. F2 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on May 21, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs fully vested on May 21, 2018. Read SEC document |
| May 21, 2018 Filed May 23, 2018 20:08 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 8,373 | $5.61 | $46,972.53 |
DisclosureSEC source: 0001019056-18-000739 · white_4.xml · nonDerivative · entry 2 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,603 Read SEC document |
| May 21, 2018 Filed May 23, 2018 20:08 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 35,644 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-18-000739 · white_4.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 19:15 UTC Amendment | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 100,000 | $2.93 | $293,000.00 |
DisclosureSEC source: 0001019056-18-000465 · white_4a.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,332 F1 · price: The purchase price of $2.93 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $2.865 to $3.020, inclusive. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F2 · price: This amendment is being filed to reflect the fact that the reported transaction was a purchase and not a sale of shares of the Issuer by Mr. White. Column 3 of Table I and footnote (1) of this Form 4 as originally filed incorrectly indicated that this transaction was a sale. Those references have been corrected on this amendment to the original Form 4 to reflect that the reported transaction was a purchase. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 15:57 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 100,000 | $2.93 | $293,000.00 |
DisclosureSEC source: 0001019056-18-000463 · white_4.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,332 F1 · price: The selling price of $2.93 is reflective of the weighted average sale price. The prices for the transactions reported on this line range from $2.865 to $3.020, inclusive. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantEmployee Stock Options (Right to Buy) · Derivative | 151,600 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001019056-18-000441 · white_4.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,600 Underlying: Common Stock · 151,600 shares Expires 2028-03-09 F1 · derivative.exercise_date: On March 9, 2018, the reporting person was granted 151,600 stock options vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 01:42 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantEmployee Stock Option (right to buy) · Derivative | 75,800 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001019056-17-000551 · white_4.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,800 Underlying: Common Stock · 75,800 shares Expires 2027-05-31 F1 · date: The option grant was approved by a committee of Aptevo Therapeutics Inc.'s board of directors on February 22, 2017, subject to stockholder approval of the Amended and Restated 2016 Stock Incentive Plan (the "Plan") under which the option was granted. Aptevo Therapeutics Inc.'s stockholders approved the Plan on May 31, 2017. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 1, 2018. Read SEC document |
| May 22, 2017 Filed May 23, 2017 21:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 17,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000493 · white_4.xml · derivative · entry 4 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,644 Underlying: Common Stock · 17,828 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent on May 22, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on May 22, 2017. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent on May 22, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on May 22, 2017. Read SEC document |
| May 22, 2017 Filed May 23, 2017 21:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 35,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000493 · white_4.xml · derivative · entry 3 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,472 Underlying: Common Stock · 35,643 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on May 21, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on May 21, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| May 22, 2017 Filed May 23, 2017 21:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 17,828 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000493 · white_4.xml · nonDerivative · entry 2 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| May 22, 2017 Filed May 23, 2017 21:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 35,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000493 · white_4.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 17:30 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 453 | $10.30 Strike: $36.20 | $4,665.90 |
DisclosureSEC source: 0000911916-17-000083 · edgar.xml · derivative · entry 5 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 453 shares Expires 2027-01-03 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 17:30 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,630 | $36.88 Strike: $9.62 | $60,114.40 |
DisclosureSEC source: 0000911916-17-000083 · edgar.xml · derivative · entry 4 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,630 shares Expires 2026-07-01 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 17:30 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,897 | $40.26 Strike: $6.24 | $358,193.22 |
DisclosureSEC source: 0000911916-17-000083 · edgar.xml · derivative · entry 3 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,897 shares Expires 2026-05-10 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 17:30 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 997 | $38.00 Strike: $8.50 | $37,886.00 |
DisclosureSEC source: 0000911916-17-000083 · edgar.xml · derivative · entry 2 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 997 shares Expires 2026-01-04 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 17:30 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,577 | $37.90 Strike: $8.60 | $249,268.30 |
DisclosureSEC source: 0000911916-17-000083 · edgar.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,577 shares Expires 2025-07-09 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 75,800 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001019056-17-000240 · white_4.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,918 Underlying: Common Stock · 75,800 shares Expires 2027-02-24 F1 · derivative.exercise_date: The options vest in three equal annual installments beginning on February 24, 2018. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:22 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | GrantStock Option (Right to Buy) · Derivative | 453 | $30.35 Strike: $36.20 | $13,748.55 |
DisclosureSEC source: 0000911916-17-000024 · edgar.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453 Underlying: Common Stock · 453 shares Expires 2027-01-03 F1 · price: This option was issued to the reporting person pursuant to the CoLucid Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash compensation of $13,750. Read SEC document |
| August 03, 2016 Filed Sep 27, 2016 19:45 UTC Amendment | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 200,475 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001019056-16-001561 · white_4a.xml · derivative · entry 2 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,118 Underlying: Common Stock · 200,475 shares Expires 2026-08-03 F2 · derivative.exercise_date: The stock options were granted on August 3, 2016 and vest in three equal installments on August 3, 2017, August 3, 2018 and August 3, 2019. F3 · balance_after: This report has been amended to reflect the 35,643 options that were originally issued by Emergent and, as a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, were adjusted and assumed by the Issuer under its Converted Equity Awards Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.